Moreover, AR can induce DSB repair in prostate cancer cells [53], which prompted us to move on to a combination treatment with a PARP inhibitor and androgen receptor signaling inhibitors (ARSIs) for patients with CRPC. This evidence concerns the gene AR and Familial prostate cancer.